User menu

Real-world variability in dabigatran levels in patients with atrial fibrillation: Comment

Bibliographic reference Douxfils, Jonathan ; Chatelain, Bernard ; Dogné, Jean-Michel ; Mullier, François. Real-world variability in dabigatran levels in patients with atrial fibrillation: Comment. In: Journal of Thrombosis and Haemostasis, Vol. 13, no.6, p. 1166-1168 (2015)
Permanent URL http://hdl.handle.net/2078.1/173043
  1. Chan N. C., Coppens M., Hirsh J., Ginsberg J. S., Weitz J. I., Vanassche T., Douketis J. D., Schulman S., Eikelboom J. W., Real-world variability in dabigatran levels in patients with atrial fibrillation, 10.1111/jth.12823
  2. LIESENFELD K.-H., LEHR T., DANSIRIKUL C., REILLY P. A., CONNOLLY S. J., EZEKOWITZ M. D., YUSUF S., WALLENTIN L., HAERTTER S., STAAB A., Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial : Population pharmacokinetics of dabigatran>, 10.1111/j.1538-7836.2011.04498.x
  3. Douxfils J., Lessire S., Dincq A.-S., Hjemdahl P., Rönquist-Nii Y., Pohanka A., Gourdin M., Chatelain B., Dogné J.-M., Mullier F., Estimation of dabigatran plasma concentrations in the perioperative setting : An ex vivo study using dedicated coagulation assays, 10.1160/th14-09-0808
  4. European Medicines Agency Pradaxa - summary of product characteristics 2014 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf
  5. Health Canada Pradaxa - product monograph DIN 02312441 2015 http://webprod5.hc-sc.gc.ca/dpd-bdpp/item-iteme.do?pm-mp=00028882
  6. Food and Drug Administration Pradaxa - full prescribing information 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s024lbl.pdf
  7. MISMETTI P., LAPORTE S., New oral antithrombotics: a need for laboratory monitoring. For, 10.1111/j.1538-7836.2010.03764.x
  8. Reilly Paul A., Lehr Thorsten, Haertter Sebastian, Connolly Stuart J., Yusuf Salim, Eikelboom John W., Ezekowitz Michael D., Nehmiz Gerhard, Wang Susan, Wallentin Lars, The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients, 10.1016/j.jacc.2013.07.104
  9. Douxfils J., Dogné J.-M., Mullier F., Chatelain B., Rönquist-Nii Y., Malmström R. E., Hjemdahl P., Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate : , 10.1160/th13-03-0202
  10. Douxfils J., Mullier F., Robert S., Chatelain C., Chatelain B., Dogné J.-M., Impact of dabigatran on a large panel of routine or specific coagulation assays : Laboratory recommendations for monitoring of dabigatran etexilate, 10.1160/th11-11-0804
  11. Antovic Jovan P., Skeppholm Mika, Eintrei Jaak, Boija Elisabet Eriksson, Söderblom Lisbeth, Norberg Eva-Marie, Onelöv Liselotte, Rönquist-Nii Yuko, Pohanka Anton, Beck Olof, Hjemdahl Paul, Malmström Rickard E., Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma, 10.1007/s00228-013-1550-4
  12. Skeppholm Mika, Hjemdahl Paul, Antovic Jovan P., Muhrbeck Josephine, Eintrei Jaak, Rönquist-Nii Yuko, Pohanka Anton, Beck Olof, Malmström Rickard E., On the monitoring of dabigatran treatment in “real life” patients with atrial fibrillation, 10.1016/j.thromres.2014.06.016
  13. Hawes E. M., Deal A. M., Funk-Adcock D., Gosselin R., Jeanneret C., Cook A. M., Taylor J. M., Whinna H. C., Winkler A. M., Moll S., Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels, 10.1111/jth.12308
  14. Rao Rama B., Regarding the Effect of Dabigatran Plasma Concentrations, 10.1016/j.jacc.2014.02.610